|Bid||62.66 x 100|
|Ask||63.70 x 200|
|Day's Range||63.55 - 64.70|
|52 Week Range||46.01 - 66.10|
|PE Ratio (TTM)||23.27|
|Earnings Date||Oct 26, 2017|
|Forward Dividend & Yield||1.56 (2.39%)|
|1y Target Est||59.82|
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
Bristol-Myers Squibb (BMY) has a portfolio that includes cardiovascular, oncology, neuroscience, immuno-science, and virology drugs.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Bristol-Myers Squibb Co. with the following peers – Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc., Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Astrazeneca PLC Sponsored ADR, AbbVie, Inc., Johnson & Johnson, Celgene Corporation and Amgen Inc. (LLY-US, MRK-US, PFE-US, SNY-US, NVS-US, AZN-US, ... Read more (Read more...)
Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Opdivo to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
Is it time to get cautious on Bristol-Myers Squibb (BMY). The drug maker’s share price is falling today after Jefferies analyst Jeffrey Holford downgraded the stock from a Buy to a Hold, and shaved his 12-month price target by a dollar to $71 a share. Sure, Holford sees Bristol-Myers as a leading player in the immuno-oncology market and believes that the Street may be underestimating the potential for some of its drugs, namely the diverse set of indications it is pursuing for the cancer drug cocktail composed of Opdivo and Yervoy.
Stocks look set for a higher open this morning after the Dow and S&P closed just below new highs last week. S&P 500 futures have ticked up 0.1%, while Dow Jones Industrial Average futures have advanced ...
Bristol-Myers Squibb (BMY: NYSE) Guggenheim Securities ($65.11, Oct. 12, 2017) We are raising our price target for Bristol-Myers Squibb to $75 from $68. Our ...
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bristol-Myers Squibb Co. (NYSE: BMY ), following which we have ...
Bristol-Myers Squibb Company today announced data evaluating Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer patients whose tumors were evaluable for tumor mutation burden , from the Phase 1/2 CheckMate -032 trial.
CHAPEL HILL, N.C , Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership ...
Investors rolled into shares of Apple in September, according to TD Ameritrade, but took profits on shares of Bristol-Myers and Pfizer shares.
Bristol-Myers Squibb Company (NYSE:BMY) delivered an ROE of 30.51% over the past 12 months, which is an impressive feat relative to its industry average of 18.27% during the same period.Read More...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY. Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $5.51 billion.
Bristol-Myers Squibb Company announced that it has appointed scientific and business thought-leader, Saurabh Saha, M.D., Ph.D., as senior vice president and global head of translational medicine in the company’s R&D organization, effective today.
Two of the biggest pharma stocks with two of the most successful cancer drugs. But which is the better pick for investors?